Year in Review: HER2+ Updates in Oncology | Supplements and Featured Publications

January 17, 2022

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the data from DESTINY-Breast03 with trastuzumab deruxtecan vs T-DM1 for patients with metastatic HER2-positive breast cancer, as well as how the findings set the field up to improve outcomes for patients with brain metastases.

January 12, 2022

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

January 12, 2022

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

January 23, 2021

Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.

January 22, 2021

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.

January 14, 2021

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

January 14, 2021

Lecia V. Sequist, MD, MPH, discusses some of the advances that bore out in 2020 in HER2-mutant lung cancer and previewed anticipated developments in 2021.

January 11, 2021

The field of HER2-positive gastrointestinal malignancies witnessed a surge of data in 2020 regarding investigational agents, such as the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki, that could play a pivotal role in transforming treatment selection in the coming years.

January 07, 2021

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.